Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 523.6m

Basilea Pharmaceutica Past Earnings Performance

Past criteria checks 0/6

Basilea Pharmaceutica has been growing earnings at an average annual rate of 55.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 4.7% per year.

Key information

55.8%

Earnings growth rate

55.5%

EPS growth rate

Biotechs Industry Growth18.9%
Revenue growth rate4.7%
Return on equity-3.9%
Net Margin-0.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24
Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18
If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Revenue & Expenses Breakdown

How Basilea Pharmaceutica makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SWX:BSLN Revenue, expenses and earnings (CHF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24149-1310
31 Mar 241535310
31 Dec 2315810310
30 Sep 2316633300
30 Jun 2317556290
31 Mar 2316134290
31 Dec 2214812290
30 Sep 221506290
30 Jun 221521290
31 Mar 22150-3280
31 Dec 21148-7280
30 Sep 21130-26280
30 Jun 21112-45270
31 Mar 21120-30280
31 Dec 20128-15280
30 Sep 20134-6270
30 Jun 201413270
31 Mar 20137-10280
31 Dec 19134-22290
30 Sep 19135-23290
30 Jun 19136-24300
31 Mar 19134-28300
31 Dec 18133-31300
30 Sep 18124-26320
30 Jun 18115-21330
31 Mar 18108-20420
31 Dec 17102-19520
30 Sep 1792-32570
30 Jun 1782-44620
31 Mar 1774-48590
31 Dec 1666-51560
30 Sep 1662-55570
30 Jun 1658-59570
31 Mar 1655-61560
31 Dec 1553-62540
30 Sep 1550-57480
30 Jun 1547-52420
31 Mar 1545-47360
31 Dec 1442-42300
30 Sep 1442-38260
30 Jun 1441-35220
31 Mar 1441-34220
31 Dec 1341-33210

Quality Earnings: BSLN is currently unprofitable.

Growing Profit Margin: BSLN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BSLN is unprofitable, but has reduced losses over the past 5 years at a rate of 55.8% per year.

Accelerating Growth: Unable to compare BSLN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BSLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: BSLN has a negative Return on Equity (-3.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies